Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.
By A. List, G. Dewald, J. Bennett, A. Giagounidis, A. Raza, E. Feldman, B. Powell, P. Greenberg, D. Thomas, R. Stone and 6 more. New England Journal of Medicine, 2006
1,199 citations recorded by the source corpus.
Subfields: Genetics, Hematology
View Paper: https://www.semanticscholar.org/paper/3931f2637681d033360f27ccc9821e42ba239439
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
In Hematology
Citations in the corpus
- Ribosomopathies: human disorders of ribosome dysfunction. (2010, background): “In a Phase 2 trial in low risk MDS patients with 5q deletions, lenalidomide treatment decreased transfusion requirement in 76% of patients, and 61% of patients had a complete cytogenetic response.[26] Lenalidomide has many biological activities, including the promotion of erythropoiesis; modulation ”
- New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. (2007, background): “transfusion independence in transfusion-dependent Low/Int-1-risk MDS, with significantly greater response among patients harboring del(5q31).(50,51) Lenalidomide was also associated with a high rate of cytogenetic remission among patients with del(5q31).”